Who are Ethyl Eicosapentaenoic Acid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DHA (Docosahexaenoic Acid), Omega-3 supplements, Fish oils.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ethyl-eicosapentaenoic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ethyl Eicosapentaenoic Acid — Competitive Intelligence Brief

Ethyl Eicosapentaenoic Acid (Ethyl Eicosapentaenoic Acid) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Omega-3 polyunsaturated fatty acid. Area: Psychiatry / Cardiovascular.

marketed Omega-3 polyunsaturated fatty acid Psychiatry / Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ethyl Eicosapentaenoic Acid (Ethyl Eicosapentaenoic Acid) — New York State Psychiatric Institute. Ethyl eicosapentaenoic acid (EPA-E) is an omega-3 polyunsaturated fatty acid that reduces triglycerides and modulates inflammatory pathways.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Ethyl Eicosapentaenoic Acid TARGET	Ethyl Eicosapentaenoic Acid	New York State Psychiatric Institute	marketed	Omega-3 polyunsaturated fatty acid
DHA (Docosahexaenoic Acid)	DHA (Docosahexaenoic Acid)	Alzheimer's Disease Cooperative Study (ADCS)	phase 3	Omega-3 polyunsaturated fatty acid
Omega-3 supplements	Omega-3 supplements	University of Pennsylvania	phase 3	Dietary supplement / Omega-3 polyunsaturated fatty acid
Fish oils	Fish oils	The University of Western Australia	phase 3	Omega-3 polyunsaturated fatty acid supplement

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Omega-3 polyunsaturated fatty acid class)

Alzheimer's Disease Cooperative Study (ADCS) · 1 drug in this class
New York State Psychiatric Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ethyl Eicosapentaenoic Acid — Competitive Intelligence Brief. https://druglandscape.com/ci/ethyl-eicosapentaenoic-acid. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab